Our Solutions

Complimentary Webinar — Regulatory Submissions in Canada vs. the U.S

This webinar provides an overview of requirements for gaining approval to conduct a first-in-human (FIH) clinical trial via Health Canada’s Clinical Trial Authorization (CTA) process and the U.S. FDA’s Investigational New Drug (IND) submission process.

Watch Altasciences’ Paul Sidney, Senior Director, Compliance and Regulatory Affairs, and Dr. Joe Francisco, Chief Toxicologist, as they provide insight as to how and why the conduct of FIH clinical trials in Canada may, in some cases, provide a more expedient method to gain human clinical safety data.

This site uses cookies to store information on your computer and improve your browsing experience. By remaining on this site, you consent to the placement of these cookies. Read our Cookie Policy to learn more.


Our deep expertise and capabilities in a broad range of therapeutic areas encompasses preclinical and early clinical studies for both small molecules and biologics. We can manage your entire program, as well as provide comprehensive support research services and bioanalytical expertise.

Please see Therapeutic Areas for a fuller discussion of our capabilities and expertise.

Learn More

Working as a flexible, attentive extension of your team, we offer all you need to move your molecule forward.